Interleukin 4 inhibits the proliferation and promotes the maturation of human leukemic early B cells.
The effects of interleukin 4 (IL-4) on human leukemic precursor B-cell lines were investigated. Recombinant IL-4 (rIL-4) was added to three acute lymphoblastic leukemia-derived pre B-cell lines: Reh, Km3 and Nalm-6. Our results show that rIL-4 significantly decreases continuous proliferation of Reh and Km3 cells while Nalm-6 cells have a limited response in this respect. This rIL-4 effect is dose-dependent and can be neutralized by anti-IL-4 monoclonal antibody (mAb). Furthermore, rIL-4 down-regulated IL-3-induced proliferation of Reh cells. Phenotypic analysis of rIL-4-treated cells points to significant induction of surface marker maturation of leukemic cells by this cytokine. Together, these in vitro data suggest that IL-4: 1) inhibits the proliferation and 2) promotes the differentiation of certain human leukemic B-cell precursors.
Ouaaz
F
F
Laboratoire d'Immunologie, CNRS URA625, Unité Claude Bernard C20, Hôpital Pitié-Salpêtrière, Paris, France.
Mentz
F
F
Mossalayi
M D
MD
Schmitt
C
C
Michel
A
A
Debre
P
P
Guillosson
J J
JJ
Merle-Beral
H
H
Arock
M
M
D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis; D001402:B-Lymphocytes / Q000473:pathology*; D002455:Cell Division; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology*; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000944:Antigens, Differentiation, B-Lymphocyte; D007376:Interleukin-2; D007377:Interleukin-3; D011994:Recombinant Proteins; D015847:Interleukin-4